Pub. Date : 2002 Apr
PMID : 11914911
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. | Cyclophosphamide | aldehyde dehydrogenase 1 family member A1 | Homo sapiens |
| 2 | PURPOSE: In preclinical models, established molecular determinants of cellular sensitivity to cyclophosphamide, long a mainstay of chemotherapeutic regimens used to treat breast cancers, include the aldehyde dehydrogenases that catalyze the detoxification of this agent, namely, ALDH1A1 and ALDH3A1. | Cyclophosphamide | aldehyde dehydrogenase 1 family member A1 | Homo sapiens |
| 3 | The premise that cellular levels of ALDH1A1 and/or ALDH3A1 predict clinical responses to cyclophosphamide-based chemotherapeutic regimens was submitted to statistical analysis. | Cyclophosphamide | aldehyde dehydrogenase 1 family member A1 | Homo sapiens |
| 4 | Retrospective analysis indicated that cellular levels of ALDH1A1, but not those of ALDH3A1, were (1) significantly higher in metastatic tumor cells that had survived exposure to cyclophosphamide than in those that had not been exposed to this drug, and (2) significantly higher in metastatic tumors that did not respond (tumor size did not decrease or even increased) to subsequent treatment with cyclophosphamide-based chemotherapeutic regimens than in those that did respond (tumor size decreased) to such regimens. | Cyclophosphamide | aldehyde dehydrogenase 1 family member A1 | Homo sapiens |
| 5 | Retrospective analysis indicated that cellular levels of ALDH1A1, but not those of ALDH3A1, were (1) significantly higher in metastatic tumor cells that had survived exposure to cyclophosphamide than in those that had not been exposed to this drug, and (2) significantly higher in metastatic tumors that did not respond (tumor size did not decrease or even increased) to subsequent treatment with cyclophosphamide-based chemotherapeutic regimens than in those that did respond (tumor size decreased) to such regimens. | Cyclophosphamide | aldehyde dehydrogenase 1 family member A1 | Homo sapiens |
| 6 | The therapeutic outcome of cyclophosphamide-based chemotherapy corresponded to cellular ALDH1A1 levels in 77% of cases. | Cyclophosphamide | aldehyde dehydrogenase 1 family member A1 | Homo sapiens |
| 7 | Thus, partial or complete responses to cyclophosphamide-based chemotherapy occurred 2.3 times more often when the ALDH1A1 level was low than when it was high. | Cyclophosphamide | aldehyde dehydrogenase 1 family member A1 | Homo sapiens |